Our recent studies suggest that gemcitabine (GEM) promotes accumulation and immunosuppressive function of monocytic myeloid-derived suppressor cells (M-MDSCs) in the tumor microenvironment via the tumor cell–derived GM-CSF and efferocytosis signaling (18). The gene discussed is CSF2; the disease is neoplasm.